<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574455</url>
  </required_header>
  <id_info>
    <org_study_id>IMMU-132-05</org_study_id>
    <nct_id>NCT02574455</nct_id>
  </id_info>
  <brief_title>ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer</brief_title>
  <acronym>ASCENT</acronym>
  <official_title>Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunomedics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunomedics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international, multi-center, open-label, randomized, Phase III study in patients
      with metastatic TNBC refractory or relapsing after at least 2 prior chemotherapies (including
      a taxane) for their metastatic disease. Patients meeting eligibility will be randomized 1:1
      to receive either sacituzumab govitecan or treatment of physician choice (TPC), which needs
      to be selected prior to randomization from one of the 4 allowed regimens. Randomization will
      be stratified by number of prior chemotherapies for advanced disease (2-3 vs &gt; 3) and
      geographical location (North America vs Europe).

      Patients will be treated until progression, unacceptable toxicity, study withdrawal, or
      death, whichever comes first. Tumor progression leading to treatment withdrawal will be
      assessed by the investigator. Starting with the initial dose of sacituzumab govitecan or TPC,
      CT scans (or MRI if contrast allergic) will be obtained at least every 8 weeks until the
      occurrence of progression of disease requiring discontinuation of further treatment.All
      patients, including those prematurely terminating study participation, will be followed every
      4 weeks during the first year and every 8 weeks thereafter for survival follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an international, multi-center, open-label, randomized, Phase III study in patients
      with metastatic TNBC refractory or relapsing after at least 2 prior chemotherapies (including
      a taxane) for their metastatic disease. Earlier adjuvant or neoadjuvant treatment for more
      limited disease is allowed, but not included in the &quot;at least two prior therapies&quot; count.

      The primary objective of this study is to compare the efficacy of sacituzumab govitecan to
      the treatment of physician's choice (TPC) as measured by progression-free survival (PFS) in
      patients with metastatic TNBC previously treated with at least two systemic chemotherapy
      regimens.

      The secondary objectives of the study are to compare between the two treatment groups for:

        -  Overall Survival (OS)

        -  Independently-determined Objective Response Rate (ORR), duration of response and time to
           onset of response per RECIST 1.1 criteria

        -  Quality of life

        -  Safety (adverse events, safety laboratories, incidence of dose delays and dose
           reductions, treatment discontinuations due to adverse events)

      Exploratory objectives include exposure-response analysis for the efficacy (PFS and OS) and
      safety (incidence of Grade 3-5 adverse events, related to UGT1A1 endpoints).

      Three-hundred and twenty-eight (328) patients are anticipated to be enrolled. Approximately
      100 institutions will participate in this study, including sites in North America and Europe.

      Clinical sites will use standard ASCO/CAP criteria for the pathological diagnosis of TNBC,
      defined as negative for estrogen receptor (ER), progesterone receptor (PR) and human
      epidermal growth factor receptor 2 (HER2). Receptor results will be based on local assessment
      of the most recent biopsy findings (or other pathology reports). HER2 negative is defined as
      one of the following: 0 or 1+ by immunohistochemistry (IHC), or if IHC 2+, then fluorescence
      in situ hybridization (FISH) ratio of HER2 gene: chromosome 17 being less than 2, as per
      standard guidelines. ER- and PR-negative is defined as &lt; 1% of cells expressing hormonal
      receptors by IHC, as per standard guidelines.

      TNBC status will be reviewed centrally but these results are not required prior to
      determining eligibility.

      BRCA 1&amp;2 mutational status will be collected, if known. Baseline serum biomarkers (CA15-3,
      CA27-29, and CEA) will be measured. A single whole-blood sample will be also collected from
      all patients for determination of UGT1A1 genotype for retrospective assessment predicting of
      toxicity.

      The Sponsor will request slides from prior (archived) biopsy or surgical specimens,
      particularly for immunohistology documentation of tumor Trop-2 expression and other
      appropriate tumor markers, including topoisomerase 1; however, these results are not required
      prior to determining eligibility.

      Patients meeting eligibility will be randomized 1:1 to receive either sacituzumab govitecan
      or treatment of physician choice (TPC), which needs to be selected prior to randomization
      from one of the 4 allowed regimens. Randomization will be stratified by number of prior
      chemotherapies for advanced disease (2-3 vs &gt; 3) and geographical location (North America vs
      Europe).

      Patients will be treated until progression, unacceptable toxicity, study withdrawal, or
      death, whichever comes first. Tumor progression leading to treatment withdrawal will be
      assessed by the investigator. Starting with the initial dose of sacituzumab govitecan or TPC,
      CT scans (or MRI if contrast allergic) will be obtained at least every 6 weeks until the
      occurrence of progression of disease requiring discontinuation of further treatment. All
      images will be evaluated locally at the study site for tumor status as per RECIST1.1.
      Confirmatory CT/MRI scans are to be obtained in any patient within 4 to 6 weeks of an initial
      partial response. Additional CT or MRI scans may be performed at the discretion of the
      physician to assess disease status as medically indicated. Other study procedures during
      treatment include quality of life questionnaires, physical examination and vital signs, CBC
      (with differential and platelet counts), routine serum chemistries, serum samples for levels
      of sacituzumab govitecan, anti-drug antibodies (HAHA), concomitant medications, and adverse
      events. (See Study Procedures).

      A final study visit will be conducted 4 weeks after the last dose of sacituzumab govitecan or
      TPC for patients discontinuing study participation unless an earlier termination is required.
      The reason for study discontinuation will be documented and any adverse events or abnormal
      laboratories at that time will be followed until resolution or stabilization.

      No crossover to sacituzumab govitecan treatment will be allowed after discontinuing treatment
      in the TPC arm, but otherwise there is no restriction on subsequent therapies that a patient
      may receive after discontinuing the study.

      All patients, including those prematurely terminating study participation, will be followed
      every 4 weeks for survival follow-up. This may be by telephone and will include documentation
      of any further anti-cancer therapy they may receive. Survival status may be also documented
      from public databases .

      The use of prophylactic antipyretics, antihistamines, antiemetics, sedatives or and
      corticosteroids has not been regularly required with sacituzumab govitecan and thus should be
      used only if medically necessary. The use of such medications for patients receiving TPC is
      at the discretion of the treating physician, but must be recorded.All patients on study will
      receive best supportive care, which includes the use of growth factors or blood transfusions,
      continuing or initiating the use of corticosteroids, other palliative medications for
      complications of disease (including medications for pain and dietary support), treatment of
      any active infections, and palliative external radiation therapy for bone metastases, or
      medications for other ongoing medical conditions.The use of other anti-cancer treatment
      (besides IMMU-132 or TPC) is not permitted during this study. However, palliative and/or
      supportive medications such as bone-modifying medications (bisphosphonates or denosumab),
      and/or procedures such as radiation and surgery will be allowed at the investigator's
      discretion. After discontinuing the study, the patient may not receive any more sacituzumab
      govitecan; otherwise, there is no restriction on subsequent therapies or interventions that a
      patient may receive. Any further anti-cancer therapy should be documented.

      A 67% improvement in PFS in this relapsed/refractory metastatic TNBC patient population would
      be considered to be clinically meaningful. PFS estimates in this patient population vary from
      1.7 to 4.2 months (3 months average). For an estimate of median PFS of 3 months in the
      control TPC group, a 1:1 randomization and a 67% improvement of median PFS in the IMMU-132
      group from 3 to 5 months (corresponding to a hazard ratio of 0.6), a total sample size of 328
      patients (305 events) equally randomized between the two arms would achieve 99% power with a
      two-sided type 1 error rate of 5%, based on an accrual rate of 18.2 patients per month
      (18-month enrollment period) and a minimum follow-up of 9 months. For the secondary endpoint
      of overall survival, with an enrollment of 328 patients (and 204 expected events), and a
      two-sided 5% type 1 error rate, the study will have 82.5% power to detect an increase in
      overall survival from 10 months in the control arm to 15 months in the IMMU-132 arm
      (corresponding to a hazard ratio of 0.67).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS):</measure>
    <time_frame>3 YEARS</time_frame>
    <description>PFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS):</measure>
    <time_frame>3 YEARS</time_frame>
    <description>OS will compared between the two treatment groups.
PFS will be measured by an independent centralized and blinded group of radiology experts who will be assessing tumor response using RECIST 1.1 criteria. FDA definitions and guidance as described in Guidance for Industry:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>3 years</time_frame>
    <description>ORR will compared between the two treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>3 years</time_frame>
    <description>Duration of response will compared between the two treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of response</measure>
    <time_frame>3 years</time_frame>
    <description>Time to onset of response will compared between the two treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">328</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>IMMU-132</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sacituzumab govitecan (10 mg/kg on Days 1 and 8 of 21-day cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of Physician's Choice determined before randomization from only one of the following treatments (see Appendix 2 for more details on administration and dosing management):
Eribulin (1.4 mg/m2 IV on Days 1 and 8 of a 21-day cycle). See section 6.5.1 Capecitabine (1000-1250 mg/m2 orally twice daily on Days1-14 of a 21-day cycle). See section 6.5.2 Gemcitabine (800-1200 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle). See section 6.5.3 Vinorelbine (25 mg/m2 weekly IV on Day 1 weekly) See section 6.5.4 (Note: eligible patients with Grade 2 neuropathy should not be prescribed vinorelbine as TPC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacituzumab govitecan</intervention_name>
    <description>Sacituzumab govitecan (10 mg/kg on Days 1 and 8 of 21-day cycles)</description>
    <arm_group_label>IMMU-132</arm_group_label>
    <other_name>IMMU-132</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin</intervention_name>
    <description>Eribulin (1.4 mg/m2 IV on Days 1 and 8 of a 21-day cycle) See section 6.5.1</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Halaven</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine (1000-1250 mg/m2 orally twice daily on Days 1-14 of a 21-day cycle) See section 6.5.2</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine (800-1200 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle). See section 6.5.3</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinorelbine (25 mg/m2 IV on Day 1 weekly). See section 6.5.4 (Note: eligible patients with Grade 2 neuropathy should not be prescribed vinorelbine as TPC).</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male patients, &gt;18 years of age, able to understand and give written
             informed consent.

          -  Histologically or cytologically confirmed TNBC based on the most recent analyzed
             biopsy or other pathology specimen. TNBC determination as per local institution as per
             standard guidelines.

          -  Refractory to or relapsed after at least two prior standard therapeutic regimens for
             advanced/metastatic TNBC. Prior use of cisplatin (or carboplatin) is permitted.

          -  Prior exposure to a taxane (paclitaxel or docetaxel)-based regimen in localized or
             advanced/metastatic setting.

          -  Eligible for one of the chemotherapy options listed as TPC (Eribulin, capecitabine,
             gemcitabine, or vinorelbine) as per investigator assessment.

          -  ECOG performance score of 0 or 1 .

          -  Measurable disease by CT or MRI as per RECIST 1.1. Bone-only disease is not permitted.

          -  At least 2 weeks beyond prior treatment (chemotherapy, investigational drugs including
             small molecular inhibitors, endocrine therapy, immunotherapy and/or radiation therapy)
             or major surgery, and recovered from all acute toxicities to Grade 1 or less (except
             alopecia and peripheral neuropathy).

          -  At least 2 weeks beyond high dose systemic corticosteroids (however, low dose
             corticosteroids &lt; 20 mg prednisone or equivalent daily are permitted).

          -  Adequate hematology without ongoing transfusional support (hemoglobin &gt; 9 g/dL, ANC &gt;
             1,500 per mm3, platelets &gt; 100,000 per mm3).

          -  Adequate renal and hepatic function (creatinine ≤ 2.0 x IULN, bilirubin ≤ 1.5 IULN,
             AST and ALT ≤ 3.0 x IULN or 5 x IULN if known liver metastases).

          -  Otherwise, all toxicity at study entry &lt; Grade 1 by NCI CTCAE v4.00 (Patients with ≤
             Grade 2 neuropathy are eligible).

          -  Patients with treated, non-progressive brain metastases, off high-dose steroids (&gt;20
             mg prednisone or equivalent) for at least 4 weeks can be enrolled in the trial.

        Exclusion Criteria:

          -  Women who are pregnant or lactating.

          -  Women of childbearing potential or fertile men unwilling to use effective
             contraception during study until conclusion of 4-week post-treatment evaluation
             period.

          -  Patients with Gilbert's disease.

          -  Presence of bulky disease (defined as any single mass &gt; 7 cm in its greatest
             dimension). Patients with a mass over 7 cm, but otherwise eligible, may be considered
             for enrollment after discussion and approval with the medical monitor.

          -  Patients with active ≥ grade 2 anorexia, nausea or vomiting, and/or signs of
             intestinal obstruction.

          -  Patients with non-melanoma skin cancer or carcinoma in situ of the cervix are
             eligible, while patients with other prior malignancies must have had at least a 3-year
             disease-free interval.

          -  Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive.

          -  Known history of unstable angina, MI, or CHF present within 6 months or clinically
             significant cardiac arrhythmia (other than stable atrial fibrillation) requiring
             anti-arrhythmia therapy.

          -  Known history of clinically significant active COPD, or other moderate-to-severe
             chronic respiratory illness present within 6 months.

          -  Prior history of clinically significant bleeding, intestinal obstruction, or GI
             perforation within 6 months of initiation of study treatment.

          -  Infection requiring intravenous antibiotic use within one week of enrollment.

          -  Patients with a history of an anaphylactic reaction to irinotecan.

          -  Other concurrent medical or psychiatric conditions that, in the Investigator's
             opinion, may be likely to confound study interpretation or prevent completion of study
             procedures and follow-up examinations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Wegener, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Immunomedics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Horne</last_name>
    <phone>973-605-8200</phone>
    <email>hhorne@immunomedics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern Cancer Center</name>
      <address>
        <city>Daphne</city>
        <state>Alabama</state>
        <zip>36526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue DeOliveira</last_name>
      <phone>251-433-9899</phone>
      <email>Sue.DeOliveira@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Cancer Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue DeOliveira</last_name>
      <phone>251-433-9899</phone>
      <email>Sue.DeOliveira@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco (UCSF) - Innovation, Technology &amp; Alliances</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115-3010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404-2023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012-5405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Apodaca</last_name>
      <phone>303-418-7639</phone>
      <email>valerie.apodaca@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Apodaca</last_name>
      <phone>303-925-0700</phone>
      <email>Valerie.Apodaca@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Apodaco</last_name>
      <phone>303-925-0700</phone>
      <email>Valerie.Apodaco@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Apodaca</last_name>
      <phone>303-925-0700</phone>
      <email>Valerie.Apodaca@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Apodaca</last_name>
      <phone>303-925-0700</phone>
      <email>Valerie.Apodaca@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Apodaca</last_name>
      <phone>303-925-0700</phone>
      <email>Valerie.Apodaca@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Apodaca</last_name>
      <phone>303-925-0700</phone>
      <email>Valerie.Apodaca@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Apodaca</last_name>
      <phone>303-925-0700</phone>
      <email>Valerie.Apodaca@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Apodaca</last_name>
      <phone>303-925-0700</phone>
      <email>Valerie.Apodaca@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Apodaca</last_name>
      <phone>303-925-0700</phone>
      <email>Valerie.Apodaca@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Parker</city>
        <state>Colorado</state>
        <zip>80138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Apodaca</last_name>
      <phone>303-925-0700</phone>
      <email>Valerie.Apodaca@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <zip>81008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Apodaca</last_name>
      <phone>303-925-0700</phone>
      <email>Valerie.Apodaca@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Apodaca</last_name>
      <phone>393-925-0700</phone>
      <email>Valerie.Apodaca@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale School Of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510-3206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Long</last_name>
      <phone>203-852-2996</phone>
      <email>Jennifer.Long@wchn.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Castle</last_name>
      <phone>202-687-2209</phone>
      <email>bickmorj@georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist</name>
      <address>
        <city>Bonita Springs</city>
        <state>Florida</state>
        <zip>34135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Rosser</last_name>
      <phone>239-274-9893</phone>
      <email>PRosser@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Rosser</last_name>
      <phone>239-274-9893</phone>
      <email>PRosser@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Cape Coral</city>
        <state>Florida</state>
        <zip>33914</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Rosser</last_name>
      <phone>239-274-9893</phone>
      <email>PRosser@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenifer Bar-Nur</last_name>
      <phone>561-472-1696</phone>
      <email>JBar-nur@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute- Fort Myers Broadway Office</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901-8108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Rosser</last_name>
      <phone>239-274-9893</phone>
      <email>PRosser@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Lecanto</city>
        <state>Florida</state>
        <zip>34461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176-2118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Robles</last_name>
      <phone>786-596-2000</phone>
      <email>TamaraR@baptisthealth.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Health Medical Group Oncology, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandino Danieska</last_name>
      <phone>786-596-7710</phone>
      <email>DanieskaS@baptisthealth.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Rosser</last_name>
      <phone>239-274-9893</phone>
      <email>PRosser@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orlando Regional Medical Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806-2008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Rosser</last_name>
      <phone>239-274-9893</phone>
      <email>PRosser@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705-1449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Rosser</last_name>
      <phone>239-274-9893</phone>
      <email>PRosser@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Rosser</last_name>
      <phone>239-274-9893</phone>
      <email>PRosser@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Spring Hill</city>
        <state>Florida</state>
        <zip>34608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Tavares</city>
        <state>Florida</state>
        <zip>32778</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32159</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34285</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Rosser</last_name>
      <phone>239-274-9893</phone>
      <email>PRosser@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34292</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Rosser</last_name>
      <phone>239-274-9893</phone>
      <email>PRosser@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>98374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenifer Bar-Nur</last_name>
      <phone>561-472-1696</phone>
      <email>JBar-nur@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401-3406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Center - Alpharetta</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Haislip</last_name>
      <phone>770-496-9457</phone>
      <email>Sally.Haislip@gacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GCS/Annex</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Haislip</last_name>
      <phone>770-496-9457</phone>
      <email>Sally.Haislip@gacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Care - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Haislip</last_name>
      <phone>770-496-9457</phone>
      <email>Sally.Haislip@gacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Haislap</last_name>
      <phone>770-496-9457</phone>
      <email>sally.haislip@gacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GCS/Canton</name>
      <address>
        <city>Canton</city>
        <state>Georgia</state>
        <zip>30114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Haislip</last_name>
      <phone>770-496-9457</phone>
      <email>Sally.Haislip@gacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Care - Conyers</name>
      <address>
        <city>Conyers</city>
        <state>Georgia</state>
        <zip>30094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Haislip</last_name>
      <phone>770-496-9457</phone>
      <email>Sally.Haislip@gacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Care - Cumming</name>
      <address>
        <city>Cumming</city>
        <state>Georgia</state>
        <zip>30041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Haislip</last_name>
      <phone>770-496-9457</phone>
      <email>Sally.Haislip@gacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Care - Decatur</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Haislip</last_name>
      <phone>770-496-9457</phone>
      <email>Sally.Haislip@gacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GCS/Stemmer</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Haislip</last_name>
      <phone>770-496-9547</phone>
      <email>Sally.Haislip@gacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Care - Stockbridge</name>
      <address>
        <city>Jonesboro</city>
        <state>Georgia</state>
        <zip>30236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Haislip</last_name>
      <phone>770-496-9457</phone>
      <email>Sally.Haislip@gacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GCS/Macon</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Haislip</last_name>
      <phone>770-496-9457</phone>
      <email>Sally.Haislip@gacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GCS/Kennestone</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Haislip</last_name>
      <phone>770-496-9457</phone>
      <email>Sally.Haislip@gacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GCS/Northside</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Haislip</last_name>
      <phone>770-496-9457</phone>
      <email>Sally.Haislip@gacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Glidden</last_name>
      <phone>847-259-4482</phone>
      <email>andrea.glidden@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center 5841 S. Maryland Ave</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Olberkyte</last_name>
      <phone>773-834-2756</phone>
      <email>rnanda@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center at Silver Cross Hospital 1900 Silver Cross Blvd</name>
      <address>
        <city>New Lenox</city>
        <state>Illinois</state>
        <zip>60451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Olberkyte</last_name>
      <phone>773-834-9774</phone>
      <email>solberkyte@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714-5905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbeth Lynn</last_name>
      <phone>847-827-9060</phone>
      <email>lisbeth.lynn@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orland Park - UCMC Center for Advanced Care 14290 South LaGrange Rd</name>
      <address>
        <city>Orland Park</city>
        <state>Illinois</state>
        <zip>60462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Olberkyte</last_name>
      <phone>773-834-9774</phone>
      <email>solberkyte@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MidAmerica Division Inc. c/o Menorah Medical Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Stawinski</last_name>
      <phone>816-276-9786</phone>
      <email>Sharon.Stawinski@hcamidwest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care Pavilion</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205-2005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Almand</last_name>
      <phone>410-964-2212</phone>
      <email>Missy.Almand@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology</name>
      <address>
        <city>Brandywine</city>
        <state>Maryland</state>
        <zip>20613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Almand</last_name>
      <phone>410-964-2212</phone>
      <email>Missy.Almand@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology</name>
      <address>
        <city>Clinton</city>
        <state>Maryland</state>
        <zip>20735</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Almand</last_name>
      <phone>410-964-2212</phone>
      <email>Missy.Almand@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Almand</last_name>
      <phone>410-964-2212</phone>
      <email>Missy.Almand@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Almand</last_name>
      <phone>410-964-2212</phone>
      <email>Missy.Almand@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Almand</last_name>
      <phone>410-964-2212</phone>
      <email>Missy.Almand@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Almand</last_name>
      <phone>410-964-2212</phone>
      <email>Missy.Almand@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center (BIDMC)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-5400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Rockwell</last_name>
      <phone>612-863-8716</phone>
      <email>Laura.Rockwell@allina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology P.A.</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Rockwell</last_name>
      <phone>612-863-8716</phone>
      <email>Laura.Rockwell@allina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suburban Imaging Northwest</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Rockwell</last_name>
      <phone>612-863-8716</phone>
      <email>Laura.Rockwell@allina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suburban Imaging</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Rockwell</last_name>
      <phone>612-863-8716</phone>
      <email>Laura.Rockwell@allina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital - Unity Campus AHL</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Rockwell</last_name>
      <phone>612-863-8716</phone>
      <email>Laura.Rockwell@allina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology P.A.</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Rockwell</last_name>
      <phone>612-863-8716</phone>
      <email>Laura.Rockwell@allina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology P.A.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Rockwell</last_name>
      <phone>612-863-8716</phone>
      <email>Laura.Rockwell@allina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abbot Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Rockwell</last_name>
      <phone>612-863-8716</phone>
      <email>Laura.Rockwell@allina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia G. Piper Cancer Center at HonorHealth</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo, 200 First Street SW</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Jensen</last_name>
      <phone>507-288-1115</phone>
      <email>jensen.jean@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MidAmerica Division Inc. c/o Menorah Medical Center</name>
      <address>
        <city>Independence</city>
        <state>Missouri</state>
        <zip>64057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Stawinski</last_name>
      <phone>816-276-9786</phone>
      <email>SharonStawinski@hcamidwest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Summa</last_name>
      <phone>314-362-0263</phone>
      <email>tracy.summa@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists - Midwest Cancer Center - Papillion</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Meays</last_name>
      <phone>402-691-6971</phone>
      <email>MMeays@nebraskacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists - Midwest Cancer Center - Paillion</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Meays</last_name>
      <phone>402-691-6971</phone>
      <email>MMeays@nebraskacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists- Midwest Cancer Center- Papillion</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046-5706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Meays</last_name>
      <phone>402-593-3141</phone>
      <email>mmeays@nebraskacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Zuchelkowski</last_name>
      <phone>518-489-2607</phone>
      <email>amy.zuchelkowski@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Zuchelkowski</last_name>
      <phone>518-262-6696</phone>
      <email>amy.zuchelkowski@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Clifton Park</city>
        <state>New York</state>
        <zip>12065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Zuchelkowski</last_name>
      <phone>518-262-6696</phone>
      <email>Amy.Zuchelkowski@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Medical Group</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213-2933</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Medical Group</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Moxon</last_name>
      <phone>503-215-2619</phone>
      <email>nicole.moxon@providence.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Chattanooga Oncology &amp; Hematology Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404-1108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobby Stillman</last_name>
      <phone>423-702-7897</phone>
      <email>kenneth.stillman@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennesee Oncology - PLLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Tucker</last_name>
      <phone>423-698-1844</phone>
      <email>KimberlyTucker@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tenesse Oncology - PLLC</name>
      <address>
        <city>Cleveland</city>
        <state>Tennessee</state>
        <zip>37311</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Tucker</last_name>
      <phone>423-698-1844</phone>
      <email>Kimberly.Tucker@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, LLC</name>
      <address>
        <city>Dickson</city>
        <state>Tennessee</state>
        <zip>37055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Wittinghill</last_name>
      <phone>615-524-4239</phone>
      <email>laura.whittinghill@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Ocology, LLC</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Whittinghill</last_name>
      <phone>615-524-4239</phone>
      <email>laura.whittinghill@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, LLC</name>
      <address>
        <city>Gallatin</city>
        <state>Tennessee</state>
        <zip>37066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Whittinghill</last_name>
      <phone>615-524-4239</phone>
      <email>laura.whittinghill@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, LLC</name>
      <address>
        <city>Hermitage</city>
        <state>Tennessee</state>
        <zip>37076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Whittinghill</last_name>
      <phone>615-524-4239</phone>
      <email>laura.whittinghill@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, LLC</name>
      <address>
        <city>Lebanon</city>
        <state>Tennessee</state>
        <zip>37090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Whittinghill</last_name>
      <phone>615-524-4239</phone>
      <email>laura.whittinghill@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, LLC</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Whittinghill</last_name>
      <phone>615-524-4239</phone>
      <email>laura.whittinghill@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Institute/Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Whittinghill</last_name>
      <phone>615-524-4239</phone>
      <email>laura.whittinghill@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, LLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Whittinghill</last_name>
      <phone>615-524-4239</phone>
      <email>laura.whittinghill@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Breast Cancer Center at One Hundred Oaks 719 Thompson Lane, Suite 25000</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Lewis-Burgan</last_name>
      <phone>615-936-3618</phone>
      <email>tammy.l.lewis-burgan@vanderbilt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Ocology, LLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Whittinghill</last_name>
      <phone>615-524-4239</phone>
      <email>laura.whittinghill@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, LLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Whittinghill</last_name>
      <phone>615-524-4239</phone>
      <email>laura.whittinghill@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tenessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Whittinghill</last_name>
      <phone>615-329-7274</phone>
      <email>laura.whittinghill@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry-Joyce Cancer Clinic 1301 Medical Center Drive 1903 The Vanderbilt Clinic Nashville, TN 37232</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Lewis-Burgan</last_name>
      <phone>615-936-3618</phone>
      <email>tammy.l.lewis-burgan@vanderbilt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, LLC</name>
      <address>
        <city>Shelbyville</city>
        <state>Tennessee</state>
        <zip>37160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Whittinghill</last_name>
      <phone>615-524-4239</phone>
      <email>laura.whittinghill@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandi Halstead</last_name>
      <phone>817-759-7022</phone>
      <email>BHalstead@txcc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Burleson</city>
        <state>Texas</state>
        <zip>76028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandi Halstead</last_name>
      <phone>817-759-7022</phone>
      <email>BHalstead@txcc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Medical City Dallas Building D</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230-6899</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila Powell</last_name>
      <phone>972-566-4291</phone>
      <email>sheila.powell@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246-2006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sulema Silva</last_name>
      <phone>214-370-1000</phone>
      <email>sulema.silva@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalene Durbin</last_name>
      <phone>940-382-1022</phone>
      <email>shalane.durbin@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104-4611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Longview Cancer Center</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Poe</last_name>
      <phone>903-757-2122</phone>
      <email>karen.poe@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075-7753</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Lee</last_name>
      <phone>972-867-3577</phone>
      <email>kristy.lee@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>US Oncology</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Poe</last_name>
      <phone>903-579-9800</phone>
      <email>karen.poe@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Weatherford</city>
        <state>Texas</state>
        <zip>76086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandi Halstead</last_name>
      <phone>817-759-7022</phone>
      <email>BHalstead@txcc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Phillips</last_name>
      <phone>703-832-5322</phone>
      <email>claudia.phillips@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Phillips</last_name>
      <phone>703-528-7303</phone>
      <email>claudia.phillips@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Blacksburg</city>
        <state>Virginia</state>
        <zip>24060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Holt</last_name>
      <phone>540-381-5291</phone>
      <email>natasha.holt@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Gobhart</last_name>
      <email>wendi.gobhardt@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031-4629</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Phillips</last_name>
      <phone>703-280-5390</phone>
      <email>claudia.phillips@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Gainesville</city>
        <state>Virginia</state>
        <zip>20155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Phillips</last_name>
      <email>claudia.phillips@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Gobhart</last_name>
      <email>wendi.gobhardt@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Leesburg</city>
        <state>Virginia</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Phillips</last_name>
      <phone>703-554-6800</phone>
      <email>claudia.phillips@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Low Moor</city>
        <state>Virginia</state>
        <zip>24457</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Holt</last_name>
      <email>natasha.holt@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Gobhart</last_name>
      <email>wendi.gobhardt@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates, P.C.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502-0026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendi Gobhart</last_name>
      <phone>757-466-8683</phone>
      <email>wendi.gobhardt@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Holt</last_name>
      <email>natasha.holt@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology &amp; Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Holt</last_name>
      <phone>540-774-8660</phone>
      <email>natasha.holt@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Gobhart</last_name>
      <phone>757-466-8683</phone>
      <email>wendi.gobhardt@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Woodbridge</city>
        <state>Virginia</state>
        <zip>22191</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Phillips</last_name>
      <phone>703-897-5358</phone>
      <email>claudia.phillips@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Wytheville</city>
        <state>Virginia</state>
        <zip>24382</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Holt</last_name>
      <email>natasha.holt@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Edmonds</city>
        <state>Washington</state>
        <zip>98026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Issaquah</city>
        <state>Washington</state>
        <zip>98029-6201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Issaquah</city>
        <state>Washington</state>
        <zip>98029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Summers</last_name>
      <phone>206-619-9313</phone>
      <email>lauren.summers@swedish.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Zlekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christel Fontaine</last_name>
      <phone>+0032-24775448</phone>
      <email>Christel.Fontaine@uzbrussel.be</email>
    </contact>
    <contact_backup>
      <last_name>Gerda Lauwers</last_name>
      <phone>00 32 2 4775481</phone>
      <email>Gerda.Lauwers@uzbrussel.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Bartholomeus</last_name>
      <phone>+32 2 541 32 34</phone>
      <email>Sylvie.Bartholomeus@bordet.be</email>
    </contact>
    <contact_backup>
      <last_name>+32 2 541 30 18 Tselepi</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge Wauters</last_name>
      <phone>+32 16 34 18 69</phone>
      <email>Ingeborg.wauters@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Hilde Hofkens</last_name>
      <phone>+32 16 34 05 04</phone>
      <email>Hilde.Hofkens@uzleuven.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinique et Maternite Sainte-Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Henry</last_name>
      <phone>+32 (0) 81 720 531</phone>
      <email>Stephanie.Henry@cmsenaumur.be</email>
    </contact>
    <contact_backup>
      <last_name>Benedicte Hyernaux</last_name>
      <phone>+32 (0) 81 702 824</phone>
      <email>Benedicte.Hyernaux@uclouvain.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Teresa Herrera, As Xubias, 84</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belen Lopez</last_name>
      <phone>+34 98178000 ex 292872</phone>
      <email>belen.lopez.cortabitarte@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Marcia</last_name>
      <phone>+34 97 676 55 00</phone>
      <email>mmacia@parcdesalutmar.cat</email>
    </contact>
    <contact_backup>
      <last_name>Maria Martinez Garcia</last_name>
      <phone>+34 93 248 31 37</phone>
      <email>MariaMartinezGarcia@parcdesalutmar.cat</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Alonso Lezcana</last_name>
      <phone>+34 93274 60 00 4695</phone>
      <email>J.Alonsovhebron@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Enric Alvarez</last_name>
      <phone>=34 93274 60 00 4707</phone>
      <email>ealvarez@vhio.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia Hospitalet, Avenida Gran Via 199-203</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Pamias Nogué</last_name>
      <phone>+3493260 73 33</phone>
      <email>mpamies@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Cortes Castan</last_name>
      <phone>+34 93 238 16 61</phone>
      <email>jacortes@vhio.net</email>
    </contact>
    <contact_backup>
      <last_name>Olaya Hernandez</last_name>
      <phone>+34 91 336 82 63</phone>
      <email>Olaya.Hernandez@salud.madrid.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Caballero</last_name>
      <phone>+34 9 1390 80 00</phone>
      <phone_ext>1740</phone_ext>
      <email>scaballero@h12o.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Caballero</last_name>
      <phone>+34 91 390 80 00 EXT1740</phone>
      <email>scaballero@h12o.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Santiago (CHUS) - Hospital Clinco Universaitario</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Lopez Lopez</last_name>
      <phone>+34 98 195 05 11</phone>
      <email>Rafael.Lopez.Lopez@sergas.es</email>
    </contact>
    <contact_backup>
      <last_name>Estiban Mendez</last_name>
      <phone>+34 98 195 05 11</phone>
      <email>Estiban86@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Angeles Oyarzabal</last_name>
      <phone>+34 67 15 333 19</phone>
      <email>oyarzabalma@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2015</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

